SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    H Eda, L Santo, D D Cirstea, A J Yee, T A Scullen, N Nemani, Y Mishima, P R Waterman, S Arastu-Kapur, E Evans, J Singh, C J Kirk, W F Westlin, N S Raje, A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity, Leukemia, 2014, 28, 9, 1892

    CrossRef

  2. 2
    E. Gwyer Findlay, L. Danks, J. Madden, M. M. Cavanagh, K. McNamee, F. McCann, R. J. Snelgrove, S. Shaw, M. Feldmann, P. C. Taylor, N. J. Horwood, T. Hussell, OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis, Proceedings of the National Academy of Sciences, 2014, 111, 6, 2289

    CrossRef

  3. 3
    Seng-Lai Tan, Cheng Liao, Matthew C. Lucas, Christopher Stevenson, Julie A. DeMartino, Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders, Pharmacology & Therapeutics, 2013, 138, 2, 294

    CrossRef

  4. 4
    Joseph J. Buggy, Laurence Elias, Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy, International Reviews of Immunology, 2012, 31, 2, 119

    CrossRef

  5. 5
    Y.-T. Tai, B. Y. Chang, S.-Y. Kong, M. Fulciniti, G. Yang, Y. Calle, Y. Hu, J. Lin, J.-J. Zhao, A. Cagnetta, M. Cea, M. A. Sellitto, M. Y. Zhong, Q. Wang, C. Acharya, D. R. Carrasco, J. J. Buggy, L. Elias, S. P. Treon, W. Matsui, P. Richardson, N. C. Munshi, K. C. Anderson, Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma, Blood, 2012, 120, 9, 1877

    CrossRef

  6. 6
    Youridies Vattakuzhi, Sonya M. Abraham, Andrew Freidin, Andrew R. Clark, Nicole J. Horwood, Dual-specificity phosphatase 1–null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis, Arthritis & Rheumatism, 2012, 64, 7
  7. 7
    Tobias Braun, Georg Schett, Pathways for Bone Loss in Inflammatory Disease, Current Osteoporosis Reports, 2012, 10, 2, 101

    CrossRef

  8. 8
    Nicole J. Horwood, Ania M. Urbaniak, Lynett Danks, Tec Family Kinases in Inflammation and Disease, International Reviews of Immunology, 2012, 31, 2, 87

    CrossRef

  9. 9
    Thomas U. Marron, Monica Martinez-Gallo, Joyce E. Yu, Charlotte Cunningham-Rundles, Toll-like receptor 4–, 7–, and 8–activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines, Journal of Allergy and Clinical Immunology, 2012, 129, 1, 184

    CrossRef

  10. 10
    Lionel B. Ivashkiv, Baohong Zhao, Kyung-Hyun Park-Min, Masamichi Takami, Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8, Annals of the New York Academy of Sciences, 2011, 1237, 1